How do typical antipsychotics differ from atypical antipsychotics?

Typical antipsychotics and atypical antipsychotics primarily differ in their development timeline and the understanding of their mechanisms and effects. Typical antipsychotics were first developed in the 1950s and primarily target the dopaminergic system, specifically the D2 receptors, which are linked to the positive symptoms of schizophrenia, such as hallucinations and delusions.

In contrast, atypical antipsychotics emerged later, beginning in the 1990s, and are designed to address both positive and negative symptoms of schizophrenia. They not only block dopamine receptors but also interact with other neurotransmitter systems such as serotonin receptors, which can help mitigate side effects commonly associated with typical antipsychotics. This development over time reflects a shift in understanding mental health treatment and a broader approach to addressing a patient's symptoms.

The other options do not accurately represent the key differences between typical and atypical antipsychotics. The method of delivery is not a distinguishing factor, as both types can be administered in similar ways (oral, injectable). Additionally, neither class is primarily designed for treating depression, although some atypical antipsychotics are used as adjunctive treatments for major depressive disorder. Lastly, while therapies may differ, typical and atypical ant